Search Results - "Ogungbenro, K"

Why Has Model‐Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future by Darwich, A S, Ogungbenro, K, Vinks, A A, Powell, J R, Reny, J‐L, Marsousi, N, Daali, Y, Fairman, D, Cook, J, Lesko, L J, McCune, J S, Knibbe, C A J, Wildt, S N, Leeder, J S, Neely, M, Zuppa, A F, Vicini, P, Aarons, L, Johnson, T N, Boiani, J, Rostami‐Hodjegan, A

“…Patient groups prone to polypharmacy and special subpopulations are susceptible to suboptimal treatment. Refined dosing in special populations is imperative to…”
Get full text

Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers by Felton, T W, Ogungbenro, K, Boselli, E, Hope, W W, Rodvold, K A

“…Severe infections of the respiratory tracts of critically ill patients are common and associated with excess morbidity and mortality. Piperacillin is commonly…”
Get full text

Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen? by Kontou, A, Sarafidis, K, Begou, O, Gika, H G, Tsiligiannis, A, Ogungbenro, K, Dokoumetzidis, A, Agakidou, E, Roilides, E

“…Our objective was to develop a population pharmacokinetic (PK) model in order to evaluate the currently recommended dosing regimen in term and preterm…”
Get full text

Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4–5 December 2014) by Musuamba, FT, Manolis, E, Holford, N, Cheung, SYA, Friberg, LE, Ogungbenro, K, Posch, M, Yates, JWT, Berry, S, Thomas, N, Corriol‐Rohou, S, Bornkamp, B, Bretz, F, Hooker, AC, Van der Graaf, PH, Standing, JF, Hay, J, Cole, S, Gigante, V, Karlsson, K, Dumortier, T, Benda, N, Serone, F, Das, S, Brochot, A, Ehmann, F, Hemmings, R, Rusten, I Skottheim

“…Inadequate dose selection for confirmatory trials is currently still one of the most challenging issues in drug development, as illustrated by high rates of…”
Get full text

Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients by Eymard, N, Volpert, V, Volpert, V, Kurbatova, P, Bessonov, N, Ogungbenro, K, Aarons, L, Janiaud, P, Nony, P, Nony, P, Bajard, A, Chabaud, S, Bertrand, Y, Kassaï, B, Cornu, C

“…Abstract T lymphoblastic lymphoma (T-LBL) is a rare type of lymphoma with a good prognosis with a remission rate of 85%. Patients can be completely cured or…”
Get full text

Design of population pharmacokinetic experiments using prior information by Ogungbenro, K, Aarons, L

“…A population pharmacokinetic study design is a group of elementary designs each composed of a set of sampling times to be performed in a number of subjects in…”
Get full text

Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy by Darwich, Adam S, Polasek, Thomas M, Aronson, Jeffrey K, Ogungbenro, Kayode, Wright, Daniel F.B, Achour, Brahim, Reny, Jean-Luc, Daali, Youssef, Eiermann, Birgit, Cook, Jack, Lesko, Lawrence, McLachlan, Andrew J, Rostami-Hodjegan, Amin

“…Model-informed precision dosing (MIPD) has become synonymous with modern approaches for individualizing drug therapy, in which the characteristics of each…”
Get full text

A rational approach to dose optimisation of pembrolizumab and nivolumab using cost analysis and pharmacokinetic modelling and simulation by Ogungbenro, K., Patel, A., Duncombe, R., Clark, J., Lorigan, P.

Get full text

A physiologically based pharmacokinetic model for Valproic acid in adults and children by Ogungbenro, Kayode, Aarons, Leon

“…[Display omitted] Valproic acid is an anti-convulscant drug that is widely used in the treatment of different types of epilepsy and since its introduction the…”
Get full text

The population pharmacokinetics of R‐ and S‐warfarin: effect of genetic and clinical factors by Lane, Steven, Al‐Zubiedi, Sameh, Hatch, Ellen, Matthews, Ivan, Jorgensen, Andrea L., Deloukas, Panos, Daly, Ann K., Park, B. Kevin, Aarons, Leon, Ogungbenro, Kayode, Kamali, Farhad, Hughes, Dyfrig, Pirmohamed, Munir

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • A number of pharmacokinetic studies have focused on S‐warfarin. These have shown that demographic factors, such as…”
Get full text

Design of population pharmacokinetic experiments using prior information by Ogungbenro, K., Aarons, L.

“…A population pharmacokinetic study design is a group of elementary designs each composed of a set of sampling times to be performed in a number of subjects in…”
Get full text

Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: Which measure of variability should be used? by Salem, Farzaneh, Ogungbenro, Kayode, Vajjah, Pavan, Johnson, Trevor N., Aarons, Leon, Rostami-Hodjegan, Amin

“…A new approach for calculation of sample size in pediatric clinical pharmacokinetic studies was suggested based on desired precision for a pharmacokinetic…”
Get full text

The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments by Ogungbenro, Kayode, Graham, Gordon, Gueorguieva, Ivelina, Aarons, Leon

“…We propose a new algorithm for optimising sampling times for population pharmacokinetic experiments using D-optimality. The algorithm was used in conjunction…”
Get full text

Optimal design for multivariate response pharmacokinetic models by GUEORGUIEVA, Ivelina, AARONS, Leon, OGUNGBENRO, Kayode, JORGA, Karin M, RODGERS, Trudy, ROWLAND, Malcolm

“…We address the problem of designing pharmacokinetic experiments in multivariate response situations. Criteria, based on the Fisher information matrix, whose…”
Get full text

Sample Size Calculations Based on Generalized Estimating Equations for Population Pharmacokinetic Experiments by Ogungbenro, Kayode, Aarons, Leon, Graham, Gordon

“…We present a method for calculating the sample size of a pharmacokinetic study analyzed using a mixed effects model within a hypothesis testing framework. A…”
Get full text

Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial by Chenel, Marylore, Ogungbenro, Kayode, Duval, Vincent, Laveille, Christian, Jochemsen, Roeline, Aarons, Leon

“…The objective of this paper is to determine optimal blood sampling time windows for the estimation of pharmacokinetic (PK) parameters by a population approach…”
Get full text